Mitomycin C: a clinical update.

Cancer Treat Rev

Research Advisors, 4903 Briarwood Circle, Manlius, New York 13104, USA.

Published: February 2001

Mitomycin C was reviewed in this journal 25 years ago and an update of its clinical usefulness is appropriate. The current review is based on representative publications covering clinical trials performed throughout the world. Single agent activity in each of the major neoplastic diseases has been reassessed when possible and the most important combinations evaluated. It is concluded that mitomycin C has a definite place in the treatment of localized bladder cancer, is active, but needs to be redefined, in the context of newer regimens for breast, head and neck, and non-small cell lung cancers, is active in, but is being displaced by, other drugs in cervical, gastric and pancreatic cancers, and is probably no longer of therapeutic value in colon cancer. It is also recognized that as many newer treatments have clinical success, the therapeutic role of mitomycin C will require continuing re-investigation.

Download full-text PDF

Source
http://dx.doi.org/10.1053/ctrv.2000.0202DOI Listing

Publication Analysis

Top Keywords

mitomycin
4
mitomycin clinical
4
clinical update
4
update mitomycin
4
mitomycin reviewed
4
reviewed journal
4
journal years
4
years ago
4
ago update
4
update clinical
4

Similar Publications

Intratumoral delivery of Mitomycin C using bio-responsive Gellan Gum Nanogel: In-vitro evaluation and enhanced chemotherapeutic efficacy.

Int J Biol Macromol

January 2025

Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India. Electronic address:

Intratumoral drug delivery systems hold immense promise in overcoming the limitations of conventional IV chemotherapy, particularly in enhancing therapeutic efficacy and minimizing systemic side effects. In this study, we introduce a novel redox-responsive intratumoral nanogel system that combines the biocompatibility of natural polysaccharides with the tailored properties of synthetic polymers. The nanogel features a unique cross-linked architecture incorporating redox-sensitive segments, designed to leverage the elevated glutathione levels in the tumor microenvironment for controlled drug release.

View Article and Find Full Text PDF

To report the cosmetic, clinical, and visual outcomes of a combined surgical approach for treating a corneal/limbal dermoid using excision and a three-layered amniotic membrane graft with fibrin glue. An 18-year-old female presented with impaired vision and ocular discomfort caused by a prominent dome-shaped limbal congenital dermoid on the inferotemporal cornea, resulting in a significant aesthetic concern. A full assessment, including refraction, best-corrected visual acuity (BCVA), corneal topography, aberrometry and anterior segment OCT (AS-OCT) was conducted to plan the surgical approach.

View Article and Find Full Text PDF

The transgenic MutaMouse hepatocyte mutation assay in vitro: Mutagenicity and mutation spectra of six substances with different mutagenic mechanisms.

Mutat Res Genet Toxicol Environ Mutagen

January 2025

Free University of Berlin, Institute of Pharmacy, Pharmacology and Toxicology, Berlin, Germany; BASF SE, Experimental Toxicology and Ecology, Ludwigshafen am Rhein, Germany.

Mutagenicity testing is a component of the hazard assessment of industrial chemicals, biocides, and pesticides. Mutations induced by test substances can be detected by in vitro and in vivo methods that have been adopted as OECD Test Guidelines. One of these in vivo methods is the Transgenic Rodent Assay (TGRA), OECD test guideline no.

View Article and Find Full Text PDF

Characterisation of Strains and Their Prophages That Carry Horse-Specific Leukocidin Genes .

Toxins (Basel)

January 2025

Leibniz Institute of Photonic Technology (Leibniz-IPHT), Leibniz Center for Photonics in Infection Research (LPI), Germany and InfectoGnostics Research Campus, 07745 Jena, Germany.

Leukocidins of (.) are bicomponent toxins that form polymeric pores in host leukocyte membranes, leading to cell death and/or triggering apoptosis. Some of these toxin genes are located on prophages and are associated with specific hosts.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!